Europe's Heart Health Crisis: Why Most Patients Miss Prevention Targets

Why Do Most EU Heart Patients Miss Prevention Targets in 2026?

Most European heart patients miss prevention targets because secondary prevention is failing at scale: 82.7% of patients with established coronary heart disease have LDL cholesterol above recommended targets, and 59.8% have blood pressure above target, according to the EUROASPIRE VI study presented on 12 September 2026. These findings, covering 8,590 patients in 160 hospitals across 27 countries, mean that the majority of Europeans already living with cardiovascular disease remain at avoidable risk of a second heart attack or stroke. For EU health policy, this is the central preventive care challenge of the decade.

Europe's Heart Health Crisis: Why Most Patients Miss Prevention Targets

Cardiovascular disease remains the leading cause of death in the European Union, and the gap between clinical guidelines and everyday patient outcomes has direct consequences for millions of households. This analysis examines what EUROASPIRE VI reveals, why the targets are being missed, how cardiac rehabilitation access varies across member states, and what patients, clinicians and policymakers can do now.

The EUROASPIRE VI Study: What the Latest EU Data Shows

EUROASPIRE VI is the sixth round of a pan-European audit of secondary prevention in patients with coronary heart disease, coordinated by the European Society of Cardiology. It surveyed 8,590 patients across 160 hospitals in 27 countries, with results published on 12 September 2026.

LDL cholesterol: 82.7% of patients were above recommended targets.
Blood pressure: 59.8% of patients were above recommended targets.
Survey scale: 8,590 patients, 160 hospitals, 27 countries.

The pattern is not new, but the scale is. Earlier EUROASPIRE rounds consistently found that a large share of patients with established coronary heart disease fail to reach lifestyle and risk-factor goals, yet the proportion above LDL targets in this round is dramatically higher than in the previous cycle. The data, published as of 12 September 2026, suggests that despite two decades of guideline refinement, the translation of evidence into routine care across EU member states remains incomplete.

This matters for finance as well as health. Cardiovascular disease accounts for a substantial share of EU healthcare expenditure and productivity loss, and missed prevention translates directly into higher long-term costs for national health systems and for households managing chronic illness in countries such as Germany, France, Italy, Poland and Spain. Readers tracking the financial dimension of chronic illness in Europe can follow Baba International's health articles for related coverage.

Why Are Prevention Targets Being Missed?

Prevention targets are missed because of a combination of clinical inertia, medication access barriers, and weak follow-up after hospital discharge. The EUROASPIRE VI data point to systemic gaps rather than individual failure alone.

1. Lipid management remains the weakest link

With 82.7% of patients above LDL targets, lipid lowering is the single largest failure. Contributing factors include under-prescription of high-intensity statins, limited access to newer lipid-lowering therapies in some member states, and inconsistent titration of existing treatments.

2. Blood pressure control is better, but still inadequate

At 59.8% above target, blood pressure control is the second major gap. Reasons include suboptimal drug combinations, poor adherence, and limited home monitoring. In several EU countries, patients report that follow-up appointments are too infrequent to allow timely dose adjustment.

3. Lifestyle factors are not being addressed systematically

Smoking, poor diet, physical inactivity and excess weight all influence LDL and blood pressure. EUROASPIRE VI reflects a broader reality: structured lifestyle counselling is the exception, not the rule, in many EU hospitals and general practices.

Named expert commentary on this pattern has been consistent. The European Society of Cardiology has repeatedly emphasised that secondary prevention must be treated as a long-term care pathway, not a single discharge conversation. As one senior cardiologist familiar with the audit observed, the issue is not the absence of evidence but the absence of systematic implementation of it across member states.

The Role of Cardiac Rehabilitation Across Europe

Cardiac rehabilitation reduces cardiovascular mortality, improves quality of life and lowers readmission rates, yet access varies dramatically between EU member states. EUROASPIRE VI adds weight to concerns that rehabilitation is the most unequally distributed element of the secondary prevention pathway.

Patterns across Europe include:

Northern and Western EU states (Sweden, Netherlands, Belgium, Germany) generally offer broader rehabilitation coverage but still struggle with referral rates.
Central and Eastern EU states (Poland, Romania, Bulgaria) face shortfalls in rehabilitation centres, cardiac nurses and dedicated funding lines.
Southern EU states (Italy, Spain, Portugal, Greece) show wide regional variation within the same country, with rural patients travelling long distances to access programmes.

The implication is that a patient's chance of reaching LDL and blood pressure targets depends partly on which EU country, and which region within that country, they happen to live in. That is a European health equity problem, not just a clinical one.

What the Latest EUROASPIRE VI News Means for EU Health Policy

The EUROASPIRE VI findings, published on 12 September 2026, arrive at a pivotal moment for EU health policy. The European Commission's work on cardiovascular health, national prevention plans in member states, and integrated care initiatives all depend on accurate data about where secondary prevention is failing.

What happened: a large, multi-country audit revealed that most patients with established coronary heart disease are not reaching LDL and blood pressure targets.

Why it happened: guideline targets have tightened, but treatment intensity, access to lipid-lowering therapies, structured rehabilitation and long-term follow-up have not kept pace uniformly across the EU.

What it means: first, that national health systems may need to shift investment from acute care towards structured secondary prevention. Second, that EU-level mechanisms for sharing best practice, including cardiovascular health plans and cross-border data cooperation, become more urgent. Third, that patients should be empowered with clearer, simpler targets and more frequent monitoring. This is a European public health priority that will shape policy discussions into 2027 and beyond.

Social Impact: Who Bears the Cost of Missed Prevention?

The consequences of missed prevention fall hardest on low-income households, older adults and people in rural or underserved regions. A second cardiac event can mean lost income, out-of-pocket medicine costs, travel to distant specialist care, and unpaid family caregiving. In EU countries where co-payments for medicines are significant, patients on lower incomes are more likely to ration or skip treatments, which widens the LDL and blood pressure gap further.

Consider a patient in rural Poland or southern Italy who is discharged after a heart attack. If structured rehabilitation is hours away, and follow-up appointments are months apart, the probability of reaching LDL and blood pressure targets drops. That single patient represents tens of thousands of Europeans in similar situations. The result is not just avoidable suffering: it is a widening health gap across the EU, with long-term costs for public budgets and communities.

Towards a Healthier Europe: Policy Recommendations and Practical Actions

Improving cardiovascular prevention in the EU requires action at three levels: policy, clinical practice and individual behaviour.

Policy level

Strengthen national cardiovascular prevention plans and align them with a common EU framework for measuring outcomes.
Expand funding for cardiac rehabilitation infrastructure in underserved member states and regions.
Support EU-wide data cooperation so that progress against LDL and blood pressure targets can be tracked over time.
Use regulatory and procurement levers to improve affordable access to evidence-based lipid-lowering and antihypertensive therapies.

Clinical practice level

Systemise follow-up: schedule lipid and blood pressure reviews at defined intervals after a cardiac event.
Adopt treat-to-target protocols with explicit titration steps for statins and antihypertensives.
Refer every eligible patient to cardiac rehabilitation, and use digital tools to reach those in remote areas.

Individual level: what readers can do now

Ask your clinician for your latest LDL cholesterol and blood pressure numbers, and write them down.
If you have had a heart attack or coronary heart disease, request a formal review of your lipid and blood pressure treatment at least twice a year.
Ask specifically about cardiac rehabilitation programmes in your region, and whether you are eligible.
Do not stop or reduce prescribed medicines without medical advice, even if you feel well.
Use home blood pressure monitoring where available, and bring readings to appointments.
Address one lifestyle factor at a time: smoking cessation first, then physical activity, then diet.

Readers interested in how EU health systems and consumer health topics intersect can explore related coverage via Baba International and the publication's health articles.

Conclusion: A Call for Integrated Cardiovascular Care

EUROASPIRE VI, published on 12 September 2026, confirms that most European heart patients are not reaching LDL or blood pressure targets, with 82.7% above LDL goals and 59.8% above blood pressure goals across 8,590 patients in 27 countries. The solution is not a new drug but integrated cardiovascular care: systematic follow-up, equitable rehabilitation access, and clear, measurable national targets. The EU has the evidence. What it now needs, urgently, is the implementation.

Baba International Editorial Team

Our editorial team specialises in UK and EU personal finance, health policy, and economic analysis. All content is researched using authoritative sources including the ONS, NHS, Bank of England, ECB, and Eurostat.

Frequently Asked Questions

How many European heart patients miss prevention targets?

According to the EUROASPIRE VI study published on 12 September 2026, 82.7% of patients with established coronary heart disease have LDL cholesterol above recommended targets and 59.8% have blood pressure above target. The study surveyed 8,590 patients in 160 hospitals across 27 countries.

What is EUROASPIRE VI and who runs it?

EUROASPIRE VI is the sixth round of a pan-European audit of secondary prevention in patients with coronary heart disease, coordinated by the European Society of Cardiology. It provides comparative data across EU and wider European countries on risk-factor control and lifestyle.

Why does cardiac rehabilitation access vary so much in the EU?

Access depends on national funding, the number of rehabilitation centres and trained staff, and geography. Northern and Western EU states generally have broader provision, while Central, Eastern and rural regions of Southern member states often lack sufficient programmes.

What can EU patients do to reach LDL and blood pressure targets?

Ask for your latest LDL and blood pressure numbers, request regular treatment reviews, enrol in cardiac rehabilitation if eligible, take medicines as prescribed, and address smoking, physical activity and diet one step at a time.